| Rybelsus (semaglutide oral) / Novo Nordisk |
NCT04865744: The Effect of Semaglutide on Pituitary Function |
|
|
| Completed | 4 | 10 | Europe | Semaglutide 7 MG Oral Tablet, Rybelsus 7 mg, Placebo, Semaglutide 14 MG Oral Tablet, Rybelsus 14 mg | University of Tartu | Healthy | 09/21 | 09/21 | | |
2021-001661-21: Feasibility of aggressively lowering urine albumin in individuals with kidney biopsy-proven diabetic kidney disease - A Pilot Study |
|
|
| Not yet recruiting | 4 | 20 | Europe | Tablet, Injection, Forxiga, Jardiance, Ozempic, Telmisartan, Losartan, hydrochlorthiazide, Spironolactone, Trental, Olumiant, Kerendia, Rybelsus | Herlev and Gentofte Hospital, Herlev and Gentofte Hospital | Diabetic Kidney Disease, Kidney Disease due to diabetes mellitus type 2, Diseases [C] - Hormonal diseases [C19] | | | | |
NCT04938388: Comparison of Oral Semaglutide w/ Placebo- Treatment for Latino Adults w/T2 Diabetes Receiving Enhanced Lifestyle Care |
|
|
| Terminated | 4 | 12 | US | Semaglutide Pill, Semaglutide 3 mg, Semaglutide 7 mg, Semaglutide 14 mg, Fresh organic vegetables | Sansum Diabetes Research Institute, Novo Nordisk A/S | Diabetes Mellitus, Type 2, Glucose Metabolism Disorders (Including Diabetes Mellitus) | 02/23 | 02/23 | | |
2022-004142-35: Additive Benefits of Semaglutide for open-AngLe glaucoma – an Opportunity for Neuroprotection (ABSALON) |
|
|
| Ongoing | 4 | 126 | Europe | Rybelsus, Tablet, Rybelsus | Department of Ophthalmology, Rigshospitalet, rigshospitalet | mild and moderate glaucoma, mild and moderate glaucoma, Diseases [C] - Eye Diseases [C11] | | | | |
| Recruiting | 4 | 116 | RoW | oral semaglutide, Rybelsus tablet | Asian Institute of Gastroenterology, India | Obesity, Weight Loss | 06/23 | 06/23 | | |
REALYSE, NCT05035082: A Research Study Comparing RYBELSUS® to Other Blood Sugar Lowering Tablets in People Living in America With Type 2 Diabetes |
|
|
| Active, not recruiting | 4 | 1262 | US | semaglutide, oral glucose-lowering medications (commercially available) | Novo Nordisk A/S | Diabetes Mellitus, Type 2 | 06/25 | 06/25 | | |
NCT05813249: Semaglutide in Nonalcoholic Fatty Liver Disease |
|
|
| Completed | 4 | 180 | RoW | Rybelsus Oral Product, Ozempic Injectable Product, Wegovy, Tocopherol and/or Actos | Zagazig University | Non-alcoholic Fatty Liver Disease | 02/24 | 04/24 | | |
| Enrolling by invitation | 4 | 140 | Canada | Semaglutide Treatment, Sitagliptin 100mg | University Health Network, Toronto, Novo Nordisk A/S | Liver Transplant; Complications, Diabetes Mellitus, NASH - Nonalcoholic Steatohepatitis, NAFLD | 04/24 | 12/24 | | |
| Recruiting | 4 | 140 | Europe | A computerized tomography (CT) coronary angiogram, Vicorder (Skidmore medical, UK), Blood tests for inflammation and oxidative stress markers | Swansea Bay University Health Board | Diabetes Mellitus, Acute Coronary Syndrome, Coronary Artery Disease | 04/24 | 08/24 | | |
| Recruiting | 4 | 120 | Europe, Canada, US, RoW | Metabolic surgery, Bariatric surgery, Roux-en-Y Gastric Bypass (RYGB), Sleeve Gastrectomy (SG), Incretin-Based Therapy, Glucagon-like Peptide-1 Receptor Agonist | Ali Aminian | Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD), Non-Alcoholic Fatty Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis (MASH), Liver Fibrosis, Obesity | 05/29 | 12/29 | | |
SemaFatCard, NCT06557811: Effect of Oral Semaglutide on Epicardial and Pericoronary Adipose Tissues in Type 2 Diabetes After Myocardial Infarction |
|
|
| Not yet recruiting | 4 | 88 | RoW | Semaglutide, Rybelsus | University of Sao Paulo General Hospital | Diabetic Patients, Acute Myocardial Infarction | 09/24 | 09/26 | | |
E-SEMPA, NCT06613854: Effect of Early Combination Antihyperglycemic Treatment on Metabolic Control in Individuals With Type 2 Diabetes |
|
|
| Not yet recruiting | 4 | 90 | Europe | Oral semaglutide, Rybelsus, Empagliflozin 10 mg, Jardiance | University Medical Centre Ljubljana | Type 2 Diabetes Mellitus (T2DM) | 09/27 | 12/27 | | |
| Recruiting | 4 | 104 | Europe | Semaglutide 14 MG [Rybelsus], Rybelsus, Placebo | Rigshospitalet, Denmark, Aarhus University Hospital, Odense University Hospital | Hyperglycemia, Renal Transplant Complication Primary Non-Function, Diabetes | 04/26 | 04/26 | | |
| Recruiting | 4 | 125 | US | oral semaglutide, Mixed Meal Tolerance Test (MMTT) | Massachusetts General Hospital, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Genetic Predisposition, Metabolic Diseases, Type 2 Diabetes | 05/27 | 05/27 | | |
| Recruiting | 4 | 20000 | Europe | Semaglutide Oral Tablet, Placebo oral tablet | University of Oxford, Novo Nordisk A/S | Diabetes Mellitus, Type 2 | 08/28 | 08/48 | | |
2020-002953-11: Research study to investigate how well semaglutide tablets taken once daily work in people who are overweight or living with obesity (OASIS) |
|
|
| Ongoing | 3 | 660 | Europe | Semaglutide C 25 mg, Semaglutide C 50 mg, Tablet, Rybelsus | Novo Nordisk A/S, Novo Nordisk A/S | ObesityOverweight, ObesityOverweight, Diseases [C] - Nutritional and Metabolic Diseases [C18] | | | | |
2021-006534-40: Research study looking at how well semaglutide tablets taken once daily work in people who have a body weight above the healthy range (OASIS 4) |
|
|
| Not yet recruiting | 3 | 300 | Europe | Semaglutide C 25 mg, tablet, Tablet, Rybelsus 3 mg tablets, Rybelsus 7 mg tablets, Rybelsus 14 mg tablets | Novo Nordisk A/S, Novo Nordisk A/S | Obesity, Bodyweight above the healthy range, Diseases [C] - Nutritional and Metabolic Diseases [C18] | | | | |
| Completed | 3 | 1606 | Europe, Canada, US, RoW | Oral semaglutide | Novo Nordisk A/S | Diabetes Mellitus, Type 2 | 03/23 | 03/23 | | |
| Completed | 3 | 667 | Europe, Canada, Japan, US, RoW | Oral semaglutide, Placebo (semaglutide) | Novo Nordisk A/S, Novo Nordisk A/S | Obesity, Overweight | 03/23 | 05/23 | | |
OASIS 2, NCT05132088: Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in East Asian People Who Are Overweight or Living With Obesity |
|
|
| Completed | 3 | 201 | Japan, RoW | semaglutide 50 mg, placebo (semaglutide) | Novo Nordisk A/S | Overweight and Obesity | 07/23 | 09/23 | | |
OASIS 4, NCT05564117: Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in People Who Have a Body Weight Above the Healthy Range |
|
|
| Completed | 3 | 307 | Europe, Canada, US | Semaglutide, Placebo semaglutide | Novo Nordisk A/S | Overweight, Obesity | 04/24 | 05/24 | | |
| Completed | 3 | 9651 | Europe, Canada, Japan, US, RoW | Semaglutide, Placebo (semaglutide) | Novo Nordisk A/S | Diabetes Mellitus, Type 2 | 06/24 | 08/24 | | |
ChiCTR2200061763: Canceled by the investigator. Semaglutide improves cognition in Alzheimer's disease patients by ameliorating insulin resistance and energy metabolism |
|
|
| Not yet recruiting | 3 | 68 | | Oral semaglutide intervention; Oral placebo | Union Hospital of Fujian Medical University; Union Hospital of Fujian Medical University, self-financing | Alzheimer's disease | | | | |
NN9924-7663, NCT06083675: Research Study to Compare Semaglutide Tablets With Empagliflozin or Metformin Tablets in People With Type 2 Diabetes |
|
|
| Withdrawn | 3 | 912 | Europe, US, RoW | Semaglutide, Empagliflozin, Metformin | Novo Nordisk A/S | Diabetes Mellitus, Type 2 | 01/25 | 05/27 | | |
OASIS 3, NCT05890976: Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in Chinese Adults Who Are Above a Healthy Weight Range |
|
|
| Active, not recruiting | 3 | 230 | RoW | Semaglutide, Semaglutide Placebo | Novo Nordisk A/S | Overweight, Obesity | 02/25 | 03/25 | | |
| Recruiting | 3 | 132 | Europe, US, RoW | Oral semaglutide, Placebo (semaglutide) | Novo Nordisk A/S | Diabetes Mellitus, Type 2 | 02/25 | 03/26 | | |
ACHIEVE-3, NCT06045221: A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin |
|
|
| Active, not recruiting | 3 | 1576 | Japan, US, RoW | Orforglipron, LY3502970, Semaglutide | Eli Lilly and Company | Type 2 Diabetes | 07/25 | 07/25 | | |
| Active, not recruiting | 3 | 1840 | Europe, Canada, Japan, US, RoW | Semagludtide, Placebo (semaglutide) | Novo Nordisk A/S | Early Alzheimer's Disease | 09/25 | 10/26 | | |
| Active, not recruiting | 3 | 1840 | Europe, Canada, Japan, US, RoW | Semaglutide, Placebo (semaglutide) | Novo Nordisk A/S | Early Alzheimer´s Disease | 09/25 | 10/26 | | |
| Active, not recruiting | 2/3 | 60 | US | Semaglutide 3mg and 7mg [Rybelsus], GLP-1 receptor agonist, Weight loss diet | University of Colorado, Denver, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | PCOS, Adolescent Obesity, NAFLD | 07/24 | 07/24 | | |
2021-002367-21: Fettvävens sammansättning och dess koppling till typ 2 diabetes: En studie som jämför behandling med Empagliflozin, Pioglitazon och Semaglutide |
|
|
| Not yet recruiting | 2 | 60 | Europe | Film-coated tablet, Tablet, Jardiance 25 mg filmdragerade tabletter, Actos 15 mg tabletter, Actos 45 mg tabletter, Rybelsus 3 mg tabletter, Rybelsus 7 mg tabletter, Rybelsus 14 mg tabletter | Karolinska Universitetssjukhuset, Vetenskapsrådet, Diabetesfonden, SRP Diabetes | Diabetes typ 2, Diabetes typ 2, Diseases [C] - Nutritional and Metabolic Diseases [C18] | | | | |
NCT05579977 / 2022-002834-15: Trial to Learn About the Study Medicine (PF-07081532) and Rybelsus in People With Type 2 Diabetes and Separately PF-07081532 in People With Obesity |
|
|
| Terminated | 2 | 902 | Europe, Canada, Japan, US, RoW | PF-07081532, Placebo, Rybelsus | Pfizer, Pfizer Inc. | Diabetes Mellitus, Obesity | 07/23 | 09/23 | | |
2022-002834-15: Trial to Learn About the Study Medicine (PF-07081532) and Rybelsus in People With T2DM and Separately PF-07081532 in People With Obesity Klinické hodnocení zkoumající hodnocený léčivý přípravek (PF-07081532) a přípravek Rybelsus u osob s diabetem 2. typu a samostatně podávaný přípravek PF-07081532 u osob s obezitou. |
|
|
| Not yet recruiting | 2 | 780 | RoW, Europe | 20mg PF-07081532-82, 60mg PF-07081532-82, 100mg PF-07081532-82, 3mg Rybelsus, 7mg Rybelsus, 14mg Rybelsus, PF-07081532-82, Tablet, Rybelsus | Pfizer Inc., Pfizer Inc. | Type 2 Diabetes Mellitus and Obesity, Type 2 Diabetes Mellitus and Obesity, Body processes [G] - Metabolic Phenomena [G03] | | | | |
| Recruiting | 2 | 120 | US | Intensive Behavioral Program, Semaglutide and Behavioral Program | University of Minnesota | Obesity, Childhood | 01/26 | 01/27 | | |
NCT06500429: A Study to Evaluate the Safety and Efficacy of NG101 in Adult Participants Receiving a GLP-1 Agonist |
|
|
| Completed | 2 | 120 | US | NG101, metopimazine mesylate, Placebo, Semaglutide Injectable Product | Neurogastrx, Inc. | Overweight and Obesity, Healthy | 09/24 | 09/24 | | |
NCT04466345: Semaglutide for the Treatment of Cognitive Dysfunction in Major Depressive Disorder |
|
|
| Active, not recruiting | 2 | 72 | Canada | Semaglutide, Placebo | University Health Network, Toronto | Major Depressive Disorder | 10/24 | 10/24 | | |
SOLSTICE, NCT06579105: Efficacy, Safety, and Tolerability of Once Daily Oral Administration of AZD5004 Versus Placebo for 26 Weeks in Adults With Type 2 Diabetes Mellitus. |
|
|
| Not yet recruiting | 2 | 384 | Europe, Canada, Japan, US | Placebo (placebo matching AZD5004 film-coated tablet), AZD5004, Semaglutide, Rybelsus | AstraZeneca | Diabetes Mellitus, Type 2 | 12/25 | 12/25 | | |
NCT05892432: Clinical Trial of Rybelsus (semaglutide) Among Adults with Alcohol Use Disorder (AUD) |
|
|
| Recruiting | 2 | 135 | US | Semaglutide 3 MG [Rybelsus], Rybelsus 3 mg, Semaglutide 7 MG [Rybelsus], Rybelsus 7 mg, Placebo | University of Colorado, Denver, National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Alcohol Use Disorder | 06/25 | 06/25 | | |
NCT06050577: The Effect of Oral Semaglutide on Bone Turnover in Patients With T2D: a Randomized Placebo-controlled Clinical Trial |
|
|
| Recruiting | 2 | 64 | Europe | oral Semaglutide/Rybelsus, Placebo | Odense University Hospital | Type 2 Diabetes, Osteopenia | 11/25 | 11/25 | | |
NCT05173714: Sit Less, Interact and Move More (SLIMM) 2 Study |
|
|
| Recruiting | 2 | 156 | US | SLIMM, Standard Resistance Training, Guided Resistance Training, Placebo, Semaglutide | Srinvasan Beddhu, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Stanford University | Chronic Kidney Diseases, Obesity | 12/26 | 03/27 | | |
| Recruiting | 2 | 80 | RoW | Semaglutide, Rybelsus, Intranasal insulin, Actrapid, Semaglutide placebo, Intranasal insulin placebo | Rutgers, The State University of New Jersey, Alzheimer's Association | Alzheimer Disease, Mild Cognitive Impairment, Metabolic Syndrome | 12/27 | 12/28 | | |
NCT05751720: Effect on Non-Alcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus With Gastric Inhibitory Polypeptide/Glucagon Like Peptide-1 Analogue |
|
|
| Recruiting | 1/2 | 30 | RoW | GIP/GLP-1a | Dr Adnan Agha | Non-Alcoholic Fatty Liver Disease, Non-alcoholic Steatohepatitis, Type 2 Diabetes, Liver Fat | 10/24 | 02/25 | | |
NCT05129891: A Research Study Looking at New Protein-based Tablets in Healthy Male Participants |
|
|
| Completed | 1 | 384 | Europe, Canada | Semaglutide D, Semaglutide G, Semaglutide H, Semaglutide I, NNC0385-0434 B, NNC0385-0434 C, NNC0385-0434 D, NNC0385-0434 E | Novo Nordisk A/S | Healthy Volunteers, High Blood Cholesterol Levels, Type 2 Diabetes | 02/23 | 05/23 | | |
NCT05429593: A Research Study Investigating How Semaglutide and Dapagliflozin Act in Your Body When Dosed in One Tablet |
|
|
| Completed | 1 | 152 | Europe | Semaglutide, Dapagliflozin, Semaglutide/dapagliflozin | Novo Nordisk A/S | Healthy Volunteers | 03/23 | 04/23 | | |
NCT04817644: A Research Study to See How Much Semaglutide and SNAC is in the Milk of Healthy, Breastfeeding Women Taking Semaglutide Tablets |
|
|
| Completed | 1 | 14 | US | Oral semaglutide | Novo Nordisk A/S | Diabetes Mellitus, Type 2 | 05/23 | 07/23 | | |
NCT05227196: A Research Study Looking at the Comparability of 2 Different Forms of Oral Semaglutide in Healthy People |
|
|
| Completed | 1 | 546 | Canada, US | Semaglutide D Dose 1, Semaglutide D Dose 2, Semaglutide D Dose 3, Semaglutide Dose 4, Semaglutide Dose 5, Semaglutide Dose 6 | Novo Nordisk A/S | Healthy Volunteers, Type 2 Diabetes | 06/23 | 08/23 | | |
NCT05996874: A Research Study Comparing the Effect of Different Dosing Conditions on Blood Levels of Semaglutide in a New Tablet Composition in Healthy Participants |
|
|
| Completed | 1 | 121 | Europe | Semaglutide | Novo Nordisk A/S | Healthy Participants | 04/24 | 04/24 | | |
NCT05784402: A Research Study to Compare How Much Semaglutide is Found in the Blood With Different Tablets of Oral Semaglutide in Healthy Participants |
|
|
| Completed | 1 | 264 | Canada, US | Semaglutide J, Semaglutide C | Novo Nordisk A/S | Healthy Participants | 02/24 | 03/24 | | |
NCT06097390: A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation III |
|
|
| Completed | 1 | 121 | Canada | Semaglutide | Novo Nordisk A/S | Healthy Participants | 02/24 | 03/24 | | |
| Recruiting | 1 | 24 | US | Placebo, Semaglutide (Rybelsus®) | Vanderbilt University Medical Center | Type 1 Diabetes | 03/27 | 03/27 | | |
| Recruiting | 1 | 64 | US | Placebo, Zebbo, Rybelsus Tablet, Semaglutide, Jardiance 25Mg Tablet, Empagliflozin, Metformin, Metformin Hydrochloride, Actos, Pioglitazone | The University of Texas Health Science Center at San Antonio, Baptist Health Foundation of San Antonio | Pre-Diabetes, Weight, Body, Cardiovascular Diseases | 07/27 | 07/27 | | |
ACTRN12624000765527: Evaluating the biological activity of a single dose of encapsulated oral semaglutide in healthy adults over a period of one week. |
|
|
| Not yet recruiting | N/A | 8 | | | Professor Timothy W Jones, Perth Children's Hospital, Child and Adolescent Health Service | Blood glucose control, Insulin levels | | | | |
NCT05577728: Prediction of the SEPRA Diabetes Trial in Healthcare Claims Data |
|
|
| Completed | N/A | 2316 | US | New use of semaglutide injection, New initiation of "standard of care" (SGL2i, 2nd generation SU, DPP-4i and GLP-1 RA except for semaglutide inj or oral) | Brigham and Women's Hospital | Diabetes Mellitus, Type 2 | 10/22 | 10/22 | | |
PIONEER REAL, NCT04878393: A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Japan, as Part of Local Clinical Practice |
|
|
| Completed | N/A | 650 | Japan | Oral semaglutide | Novo Nordisk A/S | Diabetes Mellitus, Type 2 | 02/23 | 02/23 | | |
PIONEER REAL, NCT04601753: A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Sweden, as Part of Local Clinical Practice |
|
|
| Completed | N/A | 194 | Europe | Oral Semaglutide | Novo Nordisk A/S | Diabetes Mellitus, Type 2 | 02/23 | 02/23 | | |
PIONEER REAL, NCT05230615: A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Italy, as Part of Local Clinical Practice |
|
|
| Completed | N/A | 458 | Europe | Oral semaglutide | Novo Nordisk A/S | Diabetes Mellitus, Type 2 | 11/23 | 11/23 | | |
SAMAS, NCT05147896: Semaglutide Anti-Atherosclerotic Mechanisms of Action Study in Type 2 Diabetes Patients |
|
|
| Recruiting | N/A | 100 | Europe | Semaglutide Oral Tablet, Rybelsus | University Medical Centre Ljubljana, University of Palermo | Diabetes Mellitus, Type 2, Atherosclerosis | 05/23 | 12/23 | | |
O-SEMA-Fast, NCT05716724: A Research Study to Understand How Oral Semaglutide Works in People With Type 2 Diabetes Who Plan to Fast During Ramadan in the United Arab Emirates, Saudi Arabia, and Kuwait |
|
|
| Completed | N/A | 288 | RoW | Semaglutide | Novo Nordisk A/S | Diabetes Mellitus, Type 2 | 07/23 | 07/23 | | |
PIONEER REAL, NCT04862923: A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in the United Kingdom, as Part of Local Clinical Practice |
|
|
| Completed | N/A | 336 | Europe | Oral semaglutide | Novo Nordisk A/S | Diabetes Mellitus, Type 2 | 08/23 | 08/23 | | |
PIONEER REAL, NCT05443334: A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Spain, as Part of Local Clinical Practice |
|
|
| Active, not recruiting | N/A | 462 | Europe | Semaglutide | Novo Nordisk A/S | Diabetes Mellitus, Type 2 | 05/24 | 05/24 | | |
DIACRON, NCT06333080: The Effect of Adherence to Oral Semaglutide on Glycaemic Control in People With Type 2 Diabetes Treated With Metformin |
|
|
| Recruiting | N/A | 20 | Europe | | Aalborg University Hospital | Diabetes Mellitus, Type 2 | 03/25 | 03/25 | | |
PIONEER REAL, NCT04537637: A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Denmark, as Part of Local Clinical Practice |
|
|
| Completed | N/A | 99 | Europe | Oral Semaglutide | Novo Nordisk A/S | Diabetes Mellitus, Type 2 | 05/23 | 05/23 | | |
| Completed | N/A | 388 | NA | Oral semaglutide | Novo Nordisk A/S | Diabetes Mellitus, Type 2 | 06/24 | 06/24 | | |
PIONEER REAL, NCT05443568: A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Israel, as Part of Local Clinical Practice |
|
|
| Enrolling by invitation | N/A | 194 | RoW | Oral semaglutide | Novo Nordisk A/S | Diabetes Mellitus, Type 2 | 11/24 | 11/24 | | |
PIONEER REAL, NCT05230589: A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Saudi Arabia, as Part of Local Clinical Practice |
|
|
| Completed | N/A | 194 | RoW | Oral semaglutide | Novo Nordisk A/S | Diabetes Mellitus, Type 2 | 03/23 | 03/23 | | |
NCT06318442: The GAPSID Study - How GLP-1 Analogues Prevent Steroid-Induced Diabetes |
|
|
| Not yet recruiting | N/A | 60 | Europe | Semaglutide Oral Product, Metformin Oral Tablet, Placebo | Imperial College London | Steroid-Induced Diabetes, Steroid Induced Hyperglycemia | 06/27 | 06/27 | | |
NN9924-4645, NCT05316662: A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Mexico, as Part of Local Clinical Practice |
|
|
| Completed | N/A | 187 | RoW | Semaglutide | Novo Nordisk A/S | Diabetes Mellitus, Type 2 | 04/24 | 04/24 | | |
PIONEER REAL, NCT05443191: A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Finland, as Part of Local Clinical Practice |
|
|
| Completed | N/A | 50 | Europe | Semaglutide | Novo Nordisk A/S | Diabetes Mellitus, Type 2 | 04/23 | 04/23 | | |
NCT06269120: SEMA-CardioDiab HUNGARY: A Research Study to Understand the Effects of Oral Semaglutide on Blood Sugar Levels, Weight, and Cardiovascular Risk in People With Type 2 Diabetes Patients in Hungary |
|
|
| Not yet recruiting | N/A | 470 | NA | Oral Semaglutide | Novo Nordisk A/S | Type 2 Diabetes | 09/24 | 09/25 | | |
REALISED, NCT06507475: Real World Effectiveness of Oral Semaglutide in Thailand Participants With Type 2 Diabetes |
|
|
| Not yet recruiting | N/A | 209 | NA | Semaglutide, Rybelsus | Novo Nordisk A/S | Diabetes Mellitus, Type 2 | 01/25 | 01/25 | | |
PIANO, NCT06608433: Glucagon-like Peptide-1 Receptor Agnoists for the Assessment of Adrenal Function |
|
|
| Not yet recruiting | N/A | 23 | NA | semaglutide, Placebo | University Hospital, Basel, Switzerland | Healthy Volunteer Study, HPA, Cortisol Deficiency, Adrenal Insufficiency | 07/25 | 08/25 | | |
DOORS, NCT05755360: A Research Study to Understand How Oral Semaglutide Works in People With Type 2 Diabetes Who Change From Dipeptidyl Peptidase-4 Inhibitor (DPP4i) Treatment to Oral Semaglutide in Italy |
|
|
| Active, not recruiting | N/A | 390 | Europe | Semaglutide | Novo Nordisk A/S | Diabetes Mellitus, Type 2 | 10/24 | 10/24 | | |
Sema-Lit, NCT06060392: Effect of Oral Semaglutide on Liver Fat and Body Composition in Liver Transplant Recipients With Diabetes Mellitus |
|
|
| Recruiting | N/A | 50 | RoW | Semaglutide Pill | Medanta, The Medicity, India | Liver Transplant; Complications, Diabete Mellitus | 12/24 | 03/25 | | |
NCT04572165: Epidemiological Assessment of the Risk for Pancreatic Cancer Associated With the Use of Semaglutide in Patients With Type 2 Diabetes - A Cohort Study Based on Nordic Registry Data |
|
|
| Enrolling by invitation | N/A | 600000 | Europe | Ozempic®, Active Comparator, Rybelsus® | Novo Nordisk A/S, Department of Public Health, University of Southern Denmark | Diabetes Mellitus, Type 2 | 12/24 | 12/24 | | |
| Recruiting | N/A | 1000 | Europe | Semaglutide Pill, Rybelsus | Medical University of Bialystok | PreDiabetes, Prediabetic State, Obesity | 12/24 | 12/24 | | |
NCT05714683: Regulatory Post Marketing Surveillance (rPMS) Study of Rybelsus (Oral Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea |
|
|
| Not yet recruiting | N/A | 600 | NA | Semaglutide, Rybelsus | Novo Nordisk A/S | Diabetes Mellitus, Type 2 | 10/26 | 10/26 | | |
Steno1, NCT06082063: Multifactorial Intervention to Reduce Cardiovascular Disease in Type 1 Diabetes |
|
|
| Not yet recruiting | N/A | 2000 | NA | Aspirin tablet, Semaglutide, Sotagliflozin, Finerenone | Steno Diabetes Center Copenhagen, Aarhus University Hospital, Steno Diabetes Center Nordjylland, Steno Diabetes Center Odense, Slagelse Hospital, Nykøbing Falster County Hospital, Zealand University Hospital, Hillerod Hospital, Denmark, Rigshospitalet, Denmark, Hvidovre University Hospital, Regionshospitalet Viborg, Skive, Randers Regional Hospital, Herning Hospital, Hospital of South West Jutland, Regionshospitalet Silkeborg, Bispebjerg Hospital, Regionshospitalet Horsens | Cardiovascular Diseases, Heart Failure, Type 1 Diabetes, Kidney Failure | 02/29 | 01/30 | | |
